Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
about
Is NF-kappaB a good target for cancer therapy? Hopes and pitfallsRoles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic ApproachesNatural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic InfectionNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewAberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cellsPediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.RelB-dependent stromal cells promote T-cell leukemogenesisCommon gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma riskHodgkin lymphoma: an update on its biology with new insights into classification.T-cell activation promotes tumorigenesis in inflammation-associated cancer.Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal typeAstragalin-induced cell death is caspase-dependent and enhances the susceptibility of lung cancer cells to tumor necrosis factor by inhibiting the NF-кB pathway.Different role of tumor necrosis factor-α polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysisStat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphomap37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesisPerforin gene mutations in 77 Chinese patients with lymphomas.I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells.Nonparametric simulation of signal transduction networks with semi-synchronized updateThe germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor.Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapymiR-301a as an NF-κB activator in pancreatic cancer cells.MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.The dynamic distribution of CARD11 at the immunological synapse is regulated by the inhibitory kinesin GAKIN.Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.Lymphotoxin alpha (LTA) polymorphism is associated with prognosis of non-Hodgkin's lymphoma in a Chinese populationPolymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsT cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesComparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).Luteinizing hormone receptor deficiency increases the susceptibility to alkylating agent-induced lymphomagenesis in mice.Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathwaysHigh Frequency of Inherited Variants in the MEFV Gene in Acute Lymphocytic Leukemia.p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expressionThe oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo.
P2860
Q24570128-DF59C593-22C3-4B24-90C2-D896E14415B9Q26752576-FD6B1D28-17F3-4B09-A07D-AF0ADAA8EF8DQ26775036-1B256725-368E-4057-9F3B-58390197D884Q27304386-DBD74F30-F890-4ECD-8970-721E0F31E187Q28476841-0F25856D-D615-4B66-98C3-A64B9F27A4C0Q30248284-920D8B62-0D43-4895-B7A6-FF13EC4616F8Q33348553-1BE1A757-C3FC-4894-BA85-D5DFD0E3A6E7Q33434511-EA1EDDD8-D5A8-40C2-A4A6-BAB04529321BQ33588862-0F037566-971B-4F56-82D8-86AC4E0F845EQ33590130-16082E7B-2CE8-40FA-8446-CB08DB648170Q33677463-A06FAC9A-74B2-4A78-9187-BB16D689CE01Q33688881-910A4018-7DE7-4FF4-BF39-696414FF883FQ33755625-B3327E36-1E76-4D30-973C-F3255F6532ABQ33761711-2AFC90D3-C470-4C9A-910C-DD052CD1B135Q33858228-ED7B5A0C-F221-433C-8D28-D19210B82A9EQ34032198-84A3C998-38FD-4C49-AEA9-9E8BD3994816Q34133753-21E9DE83-9108-4922-BE4A-2A5C37A58B8EQ34169082-AAB0F410-D841-4AC1-9CAC-163CFF8C1C3DQ34318470-CB719294-C6CB-4E81-B406-FED95BAEA443Q34384112-08680FBE-C582-4790-B37D-85089C82BDEBQ34451400-72A0C6F1-6F05-41C2-825D-613C9A70DC47Q34485753-B04D944B-23C7-4350-B2CD-3712A844B32BQ34545783-991A0C38-81EE-4B55-A328-F39A876FD84FQ34545856-F8D80750-3B64-418F-B0CD-52B41BAD9CFEQ34568850-8C7AC441-C16B-4F40-ABBA-3478A7CB2535Q34616590-C974DA4F-E949-4DE2-B66F-5EBABC106AD7Q34650781-39167E28-DE26-4ED1-BE1B-D3C5174A75E0Q34802998-115E120A-2A06-4B1D-968C-060D5E4DDF91Q34805375-16096E3C-013A-437F-9996-549A4242BD6BQ34890498-9379F83B-17D0-4228-9237-50B60D94079BQ34898306-E4C2E04C-1E04-46E3-93B2-FCD698B30C76Q34923799-720692AC-8763-4E14-8986-BC913E5A1ED8Q34983966-0A3242DC-7132-4AA8-A86C-90DA93733A70Q35033055-2354202D-657B-43D4-AE0D-DDD377878373Q35051575-BF737207-8610-4E97-817A-97BC93CC0ABCQ35163232-DB50952D-D420-49C3-873B-0C16CC6921DEQ35235728-3462ADEC-84FB-4728-AA19-2E78F3B74AEEQ35607281-DB17DC7C-3DF4-441D-BB30-9D8AE64B5F88Q35818443-610DFD1D-B872-492A-B262-3FD348BE9CD6Q35884596-D57A4D0B-E1B2-49AE-BE65-193DF4E49202
P2860
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@ast
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@en
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@nl
type
label
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@ast
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@en
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@nl
prefLabel
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@ast
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@en
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@nl
P1433
P1476
Aberrant NF-kappaB signaling i ...... and therapeutic implications.
@en
P2093
Philipp J Jost
P304
P356
10.1182/BLOOD-2006-07-025809
P407
P577
2007-04-01T00:00:00Z